Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma announced the pricing of $650 million of 2.25% convertible senior notes due 2029, up from a previously planned $400 million. The offering includes an option for initial purchasers to buy an additional $97.5 million in notes, with closing expected on January 28, 2021. These unsecured notes will bear interest at 2.25% annually and have a conversion price of approximately $97.04 per share, representing a 47.5% premium over the January 25 closing price of $65.79. Net proceeds are intended for general corporate purposes, including share repurchases and research funding.
BridgeBio Pharma (Nasdaq: BBIO) announced its plans to offer $400 million in convertible senior notes due 2029, potentially increasing by another $60 million through initial purchasers. The notes will be senior unsecured obligations, bearing interest semi-annually, with specific conversion conditions. Proceeds will fund capped call transactions, share repurchases up to $50 million, and general corporate purposes, including R&D and clinical development. However, the company will not redeem the notes before February 2026, and potential market reactions from related derivative transactions could impact stock prices.
BridgeBio Pharma and Eidos Therapeutics announced that their stockholders approved the acquisition of Eidos by BridgeBio. The merger, expected to close around January 26, 2021, allows Eidos shareholders to choose between receiving 1.85 shares of BridgeBio or $73.26 in cash for each share of Eidos. The cash consideration will be capped at $175 million and prorated if necessary. Both companies aim to leverage Eidos's investigational therapy, acoramidis, targeting transthyretin amyloidosis to enhance value for patients and investors.
BridgeBio Pharma (Nasdaq: BBIO) is set to acquire Eidos Therapeutics (Nasdaq: EIDX) with a transaction expected to close around January 26, 2021. This acquisition is subject to stockholder approvals during special meetings scheduled for January 19, 2021. Eidos shareholders can choose to receive either 1.85 shares of BridgeBio's stock or $73.26 in cash for each Eidos share they own, with the cash portion capped at $175 million. Proxy advisory firms recommend voting in favor of the merger.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on January 4, 2021, the grant of 4,126 restricted stock units to six new employees under its 2019 Inducement Equity Plan, compliant with Nasdaq Listing Rule 5635(c)(4). This plan, adopted in November 2019, aims to provide compensation incentives to attract talent within the biopharmaceutical sector. Founded in 2015, BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers with genetic drivers, boasting a pipeline of over 20 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has formed a three-year partnership with UC San Francisco (UCSF) to enhance the development of therapies for genetically driven diseases. This collaboration builds on a six-month pilot and aims to expedite the clinical translation of academic innovations into marketable treatments. BridgeBio intends to leverage UCSF's scientific expertise to efficiently bring new medicines to patients. Both organizations express enthusiasm about the partnership, emphasizing the importance of academia-industry collaborations in advancing medical research.
BridgeBio Pharma and Maze Therapeutics have launched a joint venture, Contour Therapeutics, aimed at advancing precision medicine for genetically defined cardiovascular diseases. This partnership leverages Maze's genetic drug discovery and BridgeBio's expertise in cardiac drug development. Initially, they will develop treatments for a specific genetically defined heart failure type. The collaboration builds on significant progress in targeting genetic causes of cardiovascular disease, aiming to innovate treatment approaches for this leading global health issue.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on December 1, 2020, the granting of stock options and restricted stock units to 15 new employees. A total of 15,351 stock options were granted at an exercise price of $51.13, along with 21,092 restricted stock units. This initiative was executed under the 2019 Inducement Equity Plan, aimed to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and has over 20 development programs in its pipeline.
BridgeBio Pharma has announced the FDA's acceptance of their New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor aimed at treating cholangiocarcinoma, a rare bile duct cancer. The NDA has been granted a Priority Review designation and is part of the Real-Time Oncology Review (RTOR) pilot program, expediting cancer treatments. This marks BridgeBio's second NDA acceptance, with plans for concurrent reviews in Australia and Canada through Project Orbis. Cholangiocarcinoma affects around 20,000 people annually in the U.S. and EU, with a low five-year survival rate of just 9%.
BridgeBio Pharma (Nasdaq: BBIO) and Navire Pharma have initiated a Phase 1 clinical trial for the SHP2 inhibitor BBP-398, targeting solid tumors with MAPK pathway mutations. The trial, led by MD Anderson’s David S. Hong, aims to evaluate safety and preliminary anti-tumor activity. The study consists of two parts, the first focusing on dose escalation to establish the recommended Phase 2 dose. BBP-398 emerged from collaborative research with MD Anderson, highlighting the potential of SHP2 inhibitors in treating hard-to-manage cancers.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
